NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
23 trialsNCT05704933 2026-04-06
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT06295159 2026-04-01
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07504796 2026-04-01
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
NYU Langone Health
Phase 4 Not yet recruiting
NCT07281924 2026-03-24
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
University of Wisconsin, Madison
Phase 1/2 Recruiting
NCT04697576 2026-03-10
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT07459543 2026-03-09
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Bristol-Myers Squibb
Phase 4 Not yet recruiting
NCT06999980 2026-02-19
Neo IRENIE
Melanoma Institute Australia
Phase 2 Recruiting
NCT05418972 2026-02-05
Neo ReNi II
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT06880549 2026-02-05
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT05704647 2026-01-14
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05002569 2026-01-08
RELATIVITY-098
Bristol-Myers Squibb
Phase 3 Terminated
NCT05034536 2026-01-08
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT05428007 2026-01-05
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 2 Recruiting
NCT07091695 2025-11-12
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
Bristol-Myers Squibb
Completed
NCT06624644 2025-09-10
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting
NCT03470922 2025-09-09
RELATIVITY-047
Bristol-Myers Squibb
Phase 2/3 Active not recruiting
NCT05625399 2025-08-24
RELATIVITY-127
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT06683755 2024-11-12
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT03743766 2024-09-25
Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
University of Pittsburgh
Phase 2 Completed
NCT03978611 2024-07-24
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
Bristol-Myers Squibb
Phase 1 Terminated
NCT02519322 2024-04-05
Neoadjuvant and Adjuvant Checkpoint Blockade
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03724968 2021-04-20
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated